WVP
ZYNE

Worth Venture Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Worth Venture Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-61,600
Closed -$394K – 151
2017
Q2 		$394K Buy
61,600
+42,800
+228% +$851K 0.34% 51
2017
Q1 		$96K Buy
+18,800
New +$374K 0.08% 106

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Worth Venture Partners's ZYNE Position: Q3 2017 in Review

Worth Venture Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2017, closing a stake of 43 shares — an estimated $1K sold.

Worth Venture Partners first reported a position in ZYNE in Q1 2017 and held it in 2 quarters. The position peaked at $1K in Q2 2017. 67 funds tracked by Wall St. Rank hold ZYNE as of Q3 2017.

  • Worth Venture Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2017 after selling out during the quarter.
  • Worth Venture Partners sold 43 Zynerba Pharmaceuticals, Inc shares in Q3 2017, an estimated $1K.
  • Worth Venture Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 2 quarters.
  • Worth Venture Partners's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2017.

Based on Worth Venture Partners's 13F filing for Q3 2017, filed 7 Nov 2017.